AstraZeneca’s Etcamah wins accelerated FDA approval for ESR1-mutated breast cancer
AI Summary- AstraZeneca received accelerated FDA approval for Etcamah in metastatic breast cancer.
- Etcamah is approved with CDK4/6 inhibitors for patients with ESR1 mutations.
- The decision follows an earlier European clearance for camizestrant.